How did we rapidly implement a convalescent plasma program?
| العنوان: | How did we rapidly implement a convalescent plasma program? |
|---|---|
| المؤلفون: | Lucette Hall, Evan M. Bloch, Alexandra Budhai, Betsy Jett, Jill Alberigo, Bruce S. Sachais, Aaron A.R. Tobian, Sarai Paradiso, Donna Strauss, Annie A. Wu, Christopher D. Hillyer, Beth H. Shaz |
| المصدر: | Transfusion |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Convalescent plasma, Pneumonia, Viral, Immunology, Blood Component Transfusion, 030204 cardiovascular system & hematology, Antibodies, Viral, Patient advocacy, law.invention, Betacoronavirus, Plasma, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Pandemic, Humans, Medicine, Immunology and Allergy, Pandemics, COVID-19 Serotherapy, Randomized Controlled Trials as Topic, Strategic planning, SARS-CoV-2, business.industry, Public health, Immunization, Passive, COVID-19, Investigational New Drug, Hematology, medicine.disease, How Do I?, Expanded access, Medical emergency, Coronavirus Infections, business, 030215 immunology |
| الوصف: | Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first U.S. organization creating a COVID-19 convalescent plasma program to support its use through the single-patient emergency investigational new drug, the National Expanded Access Program, and multiple randomized controlled trials. Within weeks, we were able to distribute more than 8000 products, scale up collections to more than 4000 units per week, meet hospital demand, and support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning; redeployment of staff; and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse. |
| اللغة: | English |
| تدمد: | 1537-2995 0041-1132 |
| DOI: | 10.1111/trf.15910 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d13affb9f8bc4d189bba933423e2b72Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8d13affb9f8bc4d189bba933423e2b72 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15372995 00411132 |
|---|---|
| DOI: | 10.1111/trf.15910 |